Professor Simon Wagner

Professor and Honorary Consultant in Haemato-Oncology

Simon Wagner

Contact details

  • Tel: +44 (0)116 258 7426
  • Email:
  • Office: Department of Haematology, 2nd Floor, Sandringham Building, Leicester Royal Infirmary

Personal details

Deputy Director of the Ernest and Helen Scott Haematological Research Institute

  • BSc II(i) Basic Medical Sciences with Biochemistry (London)
  • MBBS St George's Hospital Medical School (London)
  • MRCP Royal College of Physicians (UK)
  • PhD Hammersmith Hospital and Royal Postgraduate Medical School, London
  • PhD Title: Vk Gene usage in B Cell Leukaemias
  • FRCP Royal College of Physicians (UK)

Academic distinctions and national profile

  • Editor of Case Reports in Hematology


To view my publications, please use the links below:

2008 - 2010 2011 - 2012 2013


The group focuses on two areas of research connected with the development and maintenance of B-cell malignancies. Firstly the role of the microenvironment in driving survival and proliferation of chronic lymphocytic leukaemia. We have found that increased protein synthesis and cap-complex formation are features of leukaemic cells supported in vitro by culture systems that mimic the microenvironment and we are exploiting this to evaluate novel small molecule inhibitors of cap-dependent translation. Secondly we are working on signaling pathways repressed by BCL6, an oncogene that is constitutively expressed in about 40% of diffuse large B-cell lymphoma.

Understanding these pathways is important to determine how lymphoma cells survive in the absence of BCL6. BCL6 itself is a target for therapy and in collaboration with the Department of Structural Biology (Leicester) and the Department of Medicinal Chemistry (Leeds) we are developing a structure activity relationship for potential small molecule BCL6 inhibitors.

Clinical trials

I am co-investigator on numerous trials for low grade and high grade non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.

Current grants

The Kay Kendall Leukaemia Fund - £157,301
The CD40 miRNA signature in chronic lymphocytic leukaemia
2010 - 2013

Leukaemia and Lymphoma Research Fund - £204,073
Targeting translation in chronic lymphocytic leukaemia
2012 - 2015


I am supervising one PhD student at present and an MSc student.

Share this page:


Powerful pre-clinical platform for anti-cancer drug and biomarker discovery

Pre-clinical models that can accurately predict outcomes in the clinic are much sort after in the field of cancer drug discovery and development.  Read about how patient derived explants offer many advantages and are the powerful model of choice. A copy of the review, published in the British Journal of Cancer, is available by clicking this link: PDE Platform


SEND Study Success

Congratulations to Chris Avery, who with collaborating colleagues published findings of the SEND study, a multi-centre randomised trial using two different surgical protocols for mouth cancer treatment.  A nationwide first for this type of trial, using real-world data.  The paper, published in the British Journal of Cancer, is available by clicking this link: SEND Paper


Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair

Contact Details

Leicester Cancer Research Centre
Robert Kilpatrick Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 


AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.